Grant: Canada Postdoctoral Research Award (CPRA) program
Direct Payment
$140,000.00
ZDHHC20 enzyme function in the metastasis of pancreatic ductal adenocarcinoma
FY 2025-26
Summary
This research project aims to investigate the role of the enzyme ZDHHC20 in pancreatic cancer metastasis and its interactions with natural killer (NK) cells. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes, often due to metastasis. Recent findings suggest that ZDHHC20, which regulates protein modifications called S-acylation, plays a critical role in these metastatic processes. By exploring how knocking out ZDHHC20 affects PDAC/NK cell interactions and identifying key molecular targets, this study seeks to validate ZDHHC20 inhibitors as potential therapies to prevent metastasis, improving outcomes for PDAC patients.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
United Kingdom
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
536942
Name
White Rocio B
Country
United Kingdom
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
ZDHHC20 enzyme function in the metastasis of pancreatic ductal adenocarcinoma
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Base-Editing; Bump-Hole; Cancer; Inhibitors; Nanobodies; Organoids; S-Acylation
Abstract
This research project aims to investigate the role of the enzyme ZDHHC20 in pancreatic cancer metastasis and its interactions with natural killer (NK) cells. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes, often due to metastasis. Recent findings suggest that ZDHHC20, which regulates protein modifications called S-acylation, plays a critical role in these metastatic processes. By exploring how knocking out ZDHHC20 affects PDAC/NK cell interactions and identifying key molecular targets, this study seeks to validate ZDHHC20 inhibitors as potential therapies to prevent metastasis, improving outcomes for PDAC patients.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
White, Rocio B
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~